Clinical trial
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With…
NCT00083551 · University of Arkansas, Other · Completed
Key facts
| NCT number | NCT00083551 |
|---|---|
| Title | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy |
| Official title | UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy |
| Lead sponsor | University of Arkansas, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF and 3 more |
| Enrollment | 668 |
| Start date | Aug 1, 1998 |
| Primary completion | Aug 1, 2014 |
| Completion | Aug 1, 2014 |
| First posted | May 27, 2004 |
| Last update posted | Nov 23, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: